CN113096751A - Cerebral apoplexy treatment effect evaluation instrument and evaluation method thereof - Google Patents
Cerebral apoplexy treatment effect evaluation instrument and evaluation method thereof Download PDFInfo
- Publication number
- CN113096751A CN113096751A CN201911336442.2A CN201911336442A CN113096751A CN 113096751 A CN113096751 A CN 113096751A CN 201911336442 A CN201911336442 A CN 201911336442A CN 113096751 A CN113096751 A CN 113096751A
- Authority
- CN
- China
- Prior art keywords
- autofluorescence
- skin
- treatment
- treatment effect
- cerebral apoplexy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0062—Arrangements for scanning
- A61B5/0064—Body surface scanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Abstract
The invention relates to a curative effect evaluation technology, in particular to a cerebral apoplexy treatment effect evaluation instrument and an evaluation method thereof. The evaluation method provided by the invention can be used for non-invasively evaluating the treatment effect of the cerebral apoplexy by analyzing the comparison of the autofluorescence intensity and asymmetry emitted by the skin and the nails of the cerebral apoplexy patients before and after treatment, and is high in accuracy and convenient. If the autofluorescence intensity property of the skin and the nails of the stroke patient in treatment is lower than that of the skin and the nails before treatment, the better the treatment effect of the stroke is; if the properties such as the autofluorescence intensity of the skin and nails of the stroke patient during treatment are closer to or higher than the properties such as the autofluorescence intensity of the skin and nails before treatment, the treatment effect of the stroke is worse.
Description
Technical Field
The invention relates to a curative effect evaluation technology, in particular to a cerebral apoplexy treatment effect evaluation instrument and an evaluation method thereof.
Background
At present, the clinical treatment effect of the cerebral apoplexy is mainly a scale, the method needs to score by human subjectivity through indexes such as hospitalization time, nerve function, motor function and the like, and then carries out comprehensive evaluation, so that the time consumption is long, the process is complex, and the evaluation result is not objective. An objective, quantitative and efficient method for evaluating the efficacy of stroke is urgently needed. Therefore, the evaluation instrument for evaluating the stroke curative effect, which is noninvasive, rapid, simple to operate and accurate in evaluation, has great value, and the evaluation result is very helpful for the continuous treatment of stroke patients.
Disclosure of Invention
The invention aims to provide an evaluation method for stroke treatment effect, which can evaluate the stroke treatment effect noninvasively by analyzing the comparison of the autofluorescence intensities emitted by the skin and the nails of a stroke patient before and after treatment, and has high accuracy and convenience.
The invention also aims to provide special equipment for the method for evaluating the stroke treatment effect.
The purpose of the invention is realized by the following technical scheme:
a method for evaluating the treatment effect of stroke, which is characterized by comprising the following steps:
s1, dividing the patient into a plurality of test samples before treatment after the onset of disease and in different treatment processes;
s2, irradiating the skin and the nail of the patient with exciting light with the exciting light wavelength of 450-520nm to excite the autofluorescence of the skin and the nail;
s3, acquiring an autofluorescence image of the skin and the nail of the patient, wherein the wavelength of the autofluorescence image is within the range of 500-620 nm;
s4, analyzing the intensity of the autofluorescence image and the asymmetry of the autofluorescence image obtained in the step S4;
s5, obtaining the data values of the skin autofluorescence intensity and autofluorescence asymmetry of the plurality of test samples in the step S1; obtaining data values of nail autofluorescence intensity and autofluorescence asymmetry of a plurality of test samples;
s6, the autofluorescence intensity, the autofluorescence asymmetry and the treatment effect of the cerebral apoplexy in the step S5 all present a significant negative correlation relationship, and the treatment effect of the cerebral apoplexy is evaluated.
The evaluation results are shown as: if the autofluorescence intensity and the fluorescence asymmetry value of the skin or the nail of the cerebral apoplexy patient are lower than the autofluorescence intensity and the fluorescence asymmetry value of the skin or the nail before the treatment, the better the treatment effect of the cerebral apoplexy is shown; if the skin or nail autofluorescence intensity and the fluorescence asymmetry value of the stroke patient are closer to or higher than the skin or nail autofluorescence intensity before the treatment, the treatment effect of the stroke is worse.
Preferably, in step S2, the excitation of the skin autofluorescence with the excitation light includes at least one of excitation with a normal continuous light output, modulation excitation with electrical modulation, or excitation with pulsed laser light.
Preferably, in step S2, the skin is the skin of the ventral side and dorsal side of the finger; the wavelength of the exciting light is 450-500 nm.
Preferably, in step S3, an autofluorescence image with wavelength in the range of 500-580nm is obtained from the skin and nail of the patient.
Apparatus dedicated to the method of any preceding claim.
The special equipment comprises an optical system and an imaging analysis system; the optical system and the imaging analysis system are subjected to optical wavelength separation by a dichroic mirror;
the optical system comprises a light source, an optical conduction assembly and a lens assembly;
the imaging analysis system comprises a fluorescence imaging detection component and a data conduction and reconstruction component.
Further, the light source includes a single frequency, narrow band or broadband light source. Such as: including lasers, LEDs, mercury lamps, etc.
Further, the optical conduction component is a single lens or a telescope system, and the imaging depth is controlled.
Further, the fluorescence imaging detection component comprises a photomultiplier tube (PMT), an Avalanche Photo Diode (APD), a Photodiode (PD), a CCD, a CMOS and other common photodetectors.
Furthermore, the special equipment for evaluating the stroke treatment effect adopts single-mode 488nm or 473nm laser to carry out the excitation detection of subcutaneous green autofluorescence.
Furthermore, the special equipment for evaluating the treatment effect of the cerebral apoplexy adopts a frequency band between 490nm and 630nm as a wavelength range for imaging detection.
The above evaluation methods and the evaluation apparatuses according to these evaluation methods may be of non-medical purpose.
An evaluation model for evaluating the treatment effect of cerebral apoplexy has the obvious negative correlation between the autofluorescence values of skin and nails of cerebral apoplexy patients before and after treatment, and the autofluorescence asymmetry values of skin and nails before and after treatment and the treatment effect of cerebral apoplexy.
Compared with the prior art, the invention has the following beneficial effects:
1) according to the invention, the treatment effect of the cerebral apoplexy is evaluated noninvasively by analyzing the comparison of the autofluorescence intensity and the autofluorescence asymmetry emitted by the skin and the nails of the cerebral apoplexy patients before and after treatment, and the accuracy is high and convenient;
2) the evaluation equipment provided by the invention is simple to operate, short in evaluation time and high in evaluation accuracy.
Drawings
FIG. 1 is a graph showing the fluorescence intensity decrease with treatment time of autofluorescence of the ventral skin of fingers of the acute stroke population in example 1.
FIG. 2 is a graph showing the decrease of fluorescence asymmetry with treatment time in the finger ventral skin autofluorescence of the acute stroke population in example 2.
FIG. 3 is a graph showing the fluorescence intensity decrease with treatment time of autofluorescence of the dorsal skin of fingers of the acute stroke population in example 3.
FIG. 4 is a graph showing the decrease of fluorescence asymmetry with treatment time in the finger dorsal skin autofluorescence of the acute stroke population in example 4.
FIG. 5 is a graph showing the decrease of fluorescence intensity with treatment time in the case of example 5, which shows autofluorescence of nails in the acute stroke population.
FIG. 6 is a graph showing the decrease of fluorescence asymmetry with treatment time in nail autofluorescence of acute stroke population in example 6.
Detailed Description
The present invention will be described in detail with reference to examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that it would be apparent to those skilled in the art that several modifications and improvements can be made without departing from the inventive concept. All falling within the scope of the present invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The term "autofluorescence" as used herein means the phenomenon in which a biomolecule, when irradiated with excitation light of an appropriate wavelength, absorbs the energy of the excitation light into an excited state and then exits the excited state to emit light of a wavelength longer than that of the excitation light.
The term "autofluorescence asymmetry" as used herein refers to the degree of difference in properties such as autofluorescence intensity on the left and right body surfaces of the human body.
The term "excitation light" as used in the present invention means light capable of exciting a biomolecule to undergo an autofluorescence phenomenon, and its wavelength should be shorter than the autofluorescence.
The term "stroke" as used in the present invention includes ischemic stroke as well as hemorrhagic stroke.
The term "acute stroke" as used herein refers to a population that has suffered a stroke within 7 days.
Example 1:
before the acute stroke population is treated by adopting the exciting light as the blue light wave band (460-580 nm), the ventral finger skin of the patient is excited 1-3 months after treatment and 4-6 months after treatment, and then the autofluorescence imaging detection is carried out on the ventral finger skin of the patient, wherein the wavelength of the autofluorescence imaging detection is within the range of 500-580 nm. The experimental result shows that as the treatment process deepens, the left and right finger ventral autofluorescence intensity is negatively correlated with the treatment effect, that is, as the treatment effect of the acute stroke crowd increases, the finger ventral skin autofluorescence intensity decreases, and the detection result is shown in fig. 1.
Example 2:
before the acute stroke population is treated by adopting the exciting light as the blue light wave band (460-580 nm), the ventral finger skin of the patient is excited 1-3 months after treatment and 4-6 months after treatment, and then the autofluorescence imaging detection is carried out on the ventral finger skin of the patient, wherein the wavelength of the autofluorescence imaging detection is within the range of 500-580 nm. The experimental result shows that as the treatment process deepens, the left and right finger ventral autofluorescence asymmetry is negatively correlated with the treatment effect, that is, as the treatment effect increases, the finger ventral skin autofluorescence asymmetry decreases in the acute stroke population, and the detection result is shown in fig. 2.
Example 3:
before the acute stroke people are treated by adopting the exciting light as the blue light wave band (460-580 nm), the dorsal skin of the finger of the patient is excited 1-3 months after the treatment and 4-6 months after the treatment, and then the autofluorescence imaging detection is carried out on the dorsal skin of the finger of the patient, wherein the wavelength of the autofluorescence imaging detection is within the range of 500-580 nm. The experimental result shows that as the treatment process deepens, the autofluorescence intensity of the dorsal side of the left and right fingers is negatively correlated with the treatment effect, that is, as the treatment effect of the acute stroke crowd increases, the autofluorescence intensity of the dorsal side skin of the fingers decreases, and the detection result is shown in fig. 3.
Example 4:
before the acute stroke people are treated by adopting the exciting light as the blue light wave band (460-580 nm), the dorsal skin of the finger of the patient is excited 1-3 months after the treatment and 4-6 months after the treatment, and then the autofluorescence imaging detection is carried out on the dorsal skin of the finger of the patient, wherein the wavelength of the autofluorescence imaging detection is within the range of 500-580 nm. The experimental result shows that as the treatment process deepens, the autofluorescence asymmetry of the left and right finger dorsal sides is negatively correlated with the treatment effect, that is, as the treatment effect of the acute stroke crowd increases, the autofluorescence asymmetry of the finger dorsal skin decreases, and the detection result is shown in fig. 4.
Example 5:
before the acute stroke people are treated by adopting the exciting light as the blue light wave band (460-500nm), the nails of the patients are excited 1-3 months after treatment and 4-6 months after treatment, and then the autofluorescence imaging detection is carried out on the nails of the patients, wherein the wavelength of the autofluorescence imaging detection is within the range of 500-580 nm. The experimental results show that the autofluorescence intensity of the left and right nails is negatively correlated with the treatment effect along with the deepening of the treatment process, that is, the fluorescence intensity of the nails of the acute cerebral apoplexy population is reduced along with the increase of the treatment effect, and the detection results are shown in fig. 5.
Example 6:
before the acute stroke people are treated by adopting the exciting light as the blue light wave band (460-500nm), the nails of the patients are excited 1-3 months after treatment and 4-6 months after treatment, and then the autofluorescence imaging detection is carried out on the nails of the patients, wherein the wavelength of the autofluorescence imaging detection is within the range of 500-580 nm. The experimental results show that as the treatment process deepens, the autofluorescence asymmetry of the left and right nails is negatively correlated with the treatment effect, that is, as the treatment effect of the acute stroke population increases, the fluorescence asymmetry of the nails decreases, and the detection results are shown in fig. 6.
Example 7:
combining the intensity and asymmetry of fluorescence at various positions of the finger to carry out curative effect analysis and traditional curative effect scale analysis. The invention finds that the better the curative effect is evaluated by the traditional method, the lower the autofluorescence intensity of all parts of the finger is, and the smaller the asymmetry is. A new noninvasive method for rapidly and conveniently evaluating the curative effect is established.
The excitation of the skin autofluorescence with the excitation light in the present embodiment includes at least one of excitation with a normal continuous light output, modulation excitation with electrical modulation, or excitation with a pulsed laser.
It will be apparent to those skilled in the art that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Therefore, the detailed description and examples of the invention should not be construed as limiting the scope of the invention. The invention is limited only by the appended claims. All documents cited in this application are incorporated herein by reference in their entirety.
Claims (11)
1. A method for evaluating the treatment effect of stroke, which is characterized by comprising the following steps:
s1, dividing the patient into a plurality of test samples before treatment after the onset of disease and in different treatment processes;
s2, irradiating the skin and the nail of the patient with exciting light with the exciting light wavelength of 450-520nm to excite the autofluorescence of the skin and the nail;
s3, acquiring an autofluorescence image of the skin and the nail of the patient, wherein the wavelength of the autofluorescence image is within the range of 500-620 nm;
s4, analyzing the intensity of the autofluorescence image and the asymmetry of the autofluorescence image obtained in the step S4;
s5, obtaining the data values of the skin autofluorescence intensity and autofluorescence asymmetry of the plurality of test samples in the step S1; obtaining data values of nail autofluorescence intensity and autofluorescence asymmetry of a plurality of test samples;
s6, the autofluorescence intensity, the autofluorescence asymmetry and the treatment effect of the cerebral apoplexy in the step S5 all present a significant negative correlation relationship, and the treatment effect of the cerebral apoplexy is evaluated.
2. The method according to claim 1, wherein the excitation of the skin autofluorescence with the excitation light in step S2 comprises at least one of excitation with a common continuous light output, modulated excitation with electrical modulation, or excitation with pulsed laser light.
3. The method as claimed in claim 1, wherein in step S2, the wavelength of the excitation light is 450 nm and 500 nm.
4. The method as claimed in claim 1, wherein in step S3, an autofluorescence image with wavelengths in the range of 500-580nm is obtained from the skin and nail of the patient.
5. A dedicated apparatus for use with the method of any one of claims 1 to 4.
6. The dedicated device as recited in claim 5, wherein: comprises an optical system and an imaging analysis system; the optical system and the imaging analysis system are subjected to optical wavelength separation by a dichroic mirror;
the optical system comprises a light source, an optical conduction assembly and a lens assembly;
the imaging analysis system comprises a fluorescence imaging detection component and a data conduction and reconstruction component.
7. The dedicated device as recited in claim 6, wherein: the light source comprises a single frequency, narrow band or broadband light source.
8. The dedicated device as recited in claim 6, wherein: the optical conduction component uses a single lens or a telescope system to control the imaging depth.
9. The dedicated device as recited in claim 6, wherein: the device adopts single-mode 488nm or 473nm laser to carry out the excitation detection of subcutaneous green autofluorescence.
10. The dedicated device as recited in claim 6, wherein: the device uses a frequency band between 500nm and 620nm as the wavelength range for imaging detection.
11. An evaluation model for evaluating the treatment effect of cerebral apoplexy is characterized in that the autofluorescence values of skin and nails of cerebral apoplexy patients before and after treatment and the autofluorescence asymmetry values of skin and nails before and after treatment have significant negative correlation with the treatment effect of cerebral apoplexy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911336442.2A CN113096751A (en) | 2019-12-23 | 2019-12-23 | Cerebral apoplexy treatment effect evaluation instrument and evaluation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911336442.2A CN113096751A (en) | 2019-12-23 | 2019-12-23 | Cerebral apoplexy treatment effect evaluation instrument and evaluation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113096751A true CN113096751A (en) | 2021-07-09 |
Family
ID=76662981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911336442.2A Pending CN113096751A (en) | 2019-12-23 | 2019-12-23 | Cerebral apoplexy treatment effect evaluation instrument and evaluation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113096751A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105852808A (en) * | 2015-05-08 | 2016-08-17 | 上海交通大学 | In-vivo non-invasive detection method for ultraviolet-light-induced skin injury and detection device adopted by same |
| CN110403569A (en) * | 2018-04-28 | 2019-11-05 | 上海交通大学 | Rise the method and its application of comprehensive descision cerebral apoplexy based on the left-right asymmetry property of many places sites autofluorescence and intensity |
-
2019
- 2019-12-23 CN CN201911336442.2A patent/CN113096751A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105852808A (en) * | 2015-05-08 | 2016-08-17 | 上海交通大学 | In-vivo non-invasive detection method for ultraviolet-light-induced skin injury and detection device adopted by same |
| CN110403569A (en) * | 2018-04-28 | 2019-11-05 | 上海交通大学 | Rise the method and its application of comprehensive descision cerebral apoplexy based on the left-right asymmetry property of many places sites autofluorescence and intensity |
Non-Patent Citations (4)
| Title |
|---|
| 乔建梁等: "评估肿瘤化疗敏感性方法的研究进展", 《现代肿瘤医学》 * |
| 乔建梁等: "评估肿瘤化疗敏感性方法的研究进展", 《现代肿瘤医学》, vol. 16, no. 05, 25 May 2008 (2008-05-25), pages 873 - 875 * |
| 刘刚: "自体荧光诊断技术的研究进展及发展方向", 《生物医学工程学杂志》 * |
| 刘刚: "自体荧光诊断技术的研究进展及发展方向", 《生物医学工程学杂志》, vol. 32, no. 6, 31 December 2015 (2015-12-31), pages 1348 - 1353 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8357915B2 (en) | Method and device for measuring optical characteristics of an object | |
| JP2019517006A (en) | Systems, devices, and methods for time-resolved fluorescence spectroscopy | |
| Darvin et al. | Photobleaching as a method of increasing the accuracy in measuring carotenoid concentration in human skin by Raman spectroscopy | |
| TW201737864A (en) | Tissue classification method using time-resolved fluorescence spectroscopy and combination of monopolar and bipolar cortical and subcortical stimulator with time-resolved fluorescence spectroscopy | |
| CN106226275A (en) | A kind of based on fingernail autofluorescence as the detection method of biomarker of detection stroke onset and application thereof | |
| WO2015164774A1 (en) | Fluorescence guided surgical systems and methods gated on ambient light | |
| CN113950701A (en) | Imaging system for detecting intraoperative contrast agents in tissue | |
| CN108697814B (en) | Process for dosing a chromophoric agent in corneal tissue and device for controlling dosing | |
| AU2016260153B2 (en) | Method for detecting, in noninvasive in-vivo manner, skin damage induced by ultraviolet light, and detection device thereof | |
| CN113096751A (en) | Cerebral apoplexy treatment effect evaluation instrument and evaluation method thereof | |
| Zahra | Technological advancements to reduce the influence of absorption and scattering on the optical imaging | |
| CN109276230A (en) | A kind of short-wave infrared tumor imaging system and method | |
| CN113261918A (en) | Method for designing instrument for screening and detecting lung infection | |
| JP2008017899A (en) | Method of fluorescent diagnosis | |
| JP4025176B2 (en) | Photo-stimulator and biological light measuring device using the same | |
| RU2002131357A (en) | METHOD FOR IDENTIFICATION OF BIOLOGICAL TISSUE AND DEVICE FOR ITS IMPLEMENTATION | |
| JP7482894B2 (en) | Imaging system for detection of intraoperative contrast agents in tissue - Patents.com | |
| RU2515617C1 (en) | Method for identifying pituitary adenoma | |
| Kałużyński et al. | Luminescence spectroscopy measurements for skin cancer research | |
| Zhao et al. | A 12-wavelength NIR spectral tomography (NIRST) system for monitoring breast tumor response to neoadjuvant chemotherapy | |
| EP4363830A1 (en) | Optical system and methods of use | |
| Kumar et al. | Fluorescence from human oral cavity and body fluid saliva for detection of oral precancer: a comparison | |
| Kulikov et al. | Mathematical model of optical chanel of information-measuring fluorometric system | |
| RU96114745A (en) | METHOD OF DIAGNOSTICS OF ONCOLOGICAL DISEASES AND DEVICE FOR ITS IMPLEMENTATION | |
| JP2002224091A (en) | Blood sugar concentration measuring method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |